Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544.
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. New Engl J Med. 2019;380(15):1450–1462.
   PubMed Web of Science ®Google Scholar
• Liu M, Wang Y, Yang C, et al. Inhibiting both proline biosynthesis and lipogenesis synergistically suppresses tumor growth. J Exp Med. 2020;217(3). DOI:10.1084/jem.20191226.
   Web of Science ®Google Scholar
• Meng Z, Lou Z, Liu Z, et al. Crystal structure of human pyrroline-5-carboxylate reductase. J Mol Biol. 2006;359(5):1364–1377.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Nanda A, Sheriff A, et al. Consanguinity and double recessive gene pathology: cutis laxa (PYCR1) and nephrotic syndrome (PLCE1). JAMA Dermatol. 2019;155(2):257–259.
   PubMed Web of Science ®Google Scholar
• Cheng-Liang , Kuoa, Han-Yu, Choua , Yi-Chieh, Chiu Mitochondrial oxidative stress by lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis Cancer Letters . 2020 474 (2020) 138–150 .
   Web of Science ®Google Scholar
• Krishnan N, Dickman MB, Becker DF. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic Biol Med. 2008;44(4):671–681.
   PubMed Web of Science ®Google Scholar
• Zhuang J, Song Y, Ye Y, et al. PYCR1 interference inhibits cell growth and survival via c-jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. J Transl Med. 2019;17(1):343.
   PubMed Web of Science ®Google Scholar
• Ding J, Kuo ML, Su L, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis. 2017;38(5):519–531.
   PubMed Web of Science ®Google Scholar
• She Y, Mao A, Li F, et al. P5CR1 protein expression and the effect of gene-silencing on lung adenocarcinoma. #N/A. 2019;7:e6934.
   Google Scholar
• Wang D, Wang L, Zhang Y, et al. PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488. #N/A. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2019;111:588–595.
   PubMed Web of Science ®Google Scholar
• Guo J, Cheng X, Tian Y, et al. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation. Reprod Biol. 2021;21(3):100534.
   PubMed Web of Science ®Google Scholar
• Guo C, He J, Song X, et al. Pharmacological properties and derivatives of shikonin-A review in recent years. Pharmacol Res. 2019;149:104463.
   PubMed Web of Science ®Google Scholar
• Wang F, Yao X, Zhang Y, et al. Synthesis, biological function and evaluation of shikonin in cancer therapy. Fitoterapia. 2019;134:329–339.
   PubMed Web of Science ®Google Scholar
• Boulos JC, Rahama M, Hegazy MF, et al. Shikonin derivatives for cancer prevention and therapy. Cancer Lett. 2019;459:248–267.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cui JH, Meng QQ, et al. Advance in anti-tumor mechanisms of shikonin, alkannin and their derivatives. Mini Rev Med Chem. 2018;18(2):164–172.
   PubMed Web of Science ®Google Scholar
• Wang F, Mayca Pozo F, Tian D, et al. Shikonin inhibits cancer through P21 upregulation and apoptosis induction. Front Pharmacol. 2020;11:861.
   PubMed Web of Science ®Google Scholar
• Li X, Zeng X. Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/SMAD7/TGF-β signaling pathway. Cell Biol Int. 2020;44(2):467–476.
   PubMed Web of Science ®Google Scholar
• Lin HY, Han HW, Wang YS, et al. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. Chin Med. 2020;15:23.
   PubMed Web of Science ®Google Scholar
• Jia L, Zhu Z, Li H, et al. Shikonin inhibits proliferation, migration, invasion and promotes apoptosis in NCI-N87 cells via inhibition of PI3K/AKT signal pathway. Artif Cells Nanomed Biotechnol. 2019;47(1):2662–2669.
   PubMed Web of Science ®Google Scholar
• Zhang N, Peng F, Wang Y, et al. Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis. Int J Biol Sci. 2020;16(1):147–161.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kang X, Niu G, et al. Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways. Artif Cells Nanomed Biotechnol. 2019;47(1):626–635.
   PubMed Web of Science ®Google Scholar
• Ma L, Li G, Zhu H, et al. 2-methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and −2. Cancer Lett. 2014;355(1):96–105.
   PubMed Web of Science ®Google Scholar
• Fang DD, Zhu H, Tang Q, et al. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol. 2021;15(1):101244.
   PubMed Web of Science ®Google Scholar
• Li C, Yang Y, Wang H, et al. miR-362-3p suppresses ovarian cancer by inhibiting LRP8. Transl Oncol. 2021;15(1):101284.
   PubMed Web of Science ®Google Scholar
• Xu H, He Y, Lin L, et al. MiR-1207-5p targets PYCR1 to inhibit the progression of prostate cancer. Biochem Biophys Res Commun. 2021;575:56–64.
   PubMed Web of Science ®Google Scholar
• Yu L, Shi Q, Jin Y, et al. Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study. BMC Cancer. 2021;21(1):195.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chu D, Kawamura T, et al. GRIM-19 repressed hypoxia-induced invasion and EMT of colorectal cancer by repressing autophagy through inactivation of STAT3/HIF-1alpha signaling axis. J Cell Physiol. 2019;234(8):12800–12808.
   PubMed Web of Science ®Google Scholar
• Yang W, Liu J, Hou L, et al. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1alpha to overcome apoptosis in a refractory HCC cell line. Life Sci. 2021;265:118796.
   PubMed Web of Science ®Google Scholar
• Song W, Yang K, Luo J, et al. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression. Aging (Albany NY). 2021;13(3):3909–3925.
   PubMedGoogle Scholar
• Xu Y, Zuo W, Wang X, et al. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma. Int J Biol Sci. 2021;17(9):2223–2239.
   PubMed Web of Science ®Google Scholar
• Andújar I, Ríos JL, Giner RM, et al. Pharmacological properties of shikonin - a review of literature since 2002. Planta Med. 2013;79(18):1685–1697.
   PubMed Web of Science ®Google Scholar
• Gupta B, Chakraborty S, Saha S, et al. Antinociceptive properties of shikonin: in vitro and in vivo studies. Can J Physiol Pharmacol. 2016;94(7):788–796.
   PubMed Web of Science ®Google Scholar
• Liu T, Li S, Wu L, et al. Experimental study of hepatocellular carcinoma treatment by shikonin through regulating PKM2. J Hepatocell Carcinoma. 2020;7:19–31.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu SY, Zhang J, et al. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma. Am J Cancer Res. 2021;11(7):3575–3593.
   PubMed Web of Science ®Google Scholar
• Liu B, Jin J, Zhang Z, et al. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway. Biochem Cell Biol. 2019;97(4):397–405.
   PubMedGoogle Scholar
• Wei PL, Tu CC, Chen CH, et al. Shikonin suppresses the migratory ability of hepatocellular carcinoma cells. J Agric Food Chem. 2013;61(34):8191–8197.
   PubMed Web of Science ®Google Scholar
• Song J, Zhao Z, Fan X, et al. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. #N/A. 2016;7(43):70504–70515.
   Google Scholar
• Bao C, Liu T, Qian L, et al. Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway. J Cancer. 2021;12(1):76–88.
   PubMed Web of Science ®Google Scholar
• Ohsumi Y. Historical landmarks of autophagy research. Cell Res. 2014;24(1):9–23.
   PubMed Web of Science ®Google Scholar
• Onorati AV, Dyczynski M, Ojha R, et al. Targeting autophagy in cancer. Cancer. 2018;124(16):3307–3318.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B. Autophagy in human diseases. New Engl J Med. 2020;383(16):1564–1576.
   PubMed Web of Science ®Google Scholar
• Shi S, Cao H. Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway. Oncol Lett. 2014;8(3):1087–1089.
   PubMed Web of Science ®Google Scholar
• Song M, Zhang H, Chen Z, et al. Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet-activating factor-mitogen-activated protein kinase axis. Exp Ther Med. 2021;21(1):28.
   PubMed Web of Science ®Google Scholar
• Liu T, Xu L, Wang C, et al. Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/smads pathway through shikonin. J Gastroenterol Hepatol. 2019;34(1):263–276.
   PubMed Web of Science ®Google Scholar
• Ravi Amaravadi, Alec C. Kimmelman, Eileen White, Recent insights into the function of autophagy in cancer GENES & DEVELOPMENT 2016 30: 1913–1930 .
   PubMed Web of Science ®Google Scholar
• Xu Z, Han X, Ou D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2):575–587.
   PubMed Web of Science ®Google Scholar
• Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699–707.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang Q, Mo W, et al. The protective effects of shikonin on hepatic ischemia/reperfusion injury are mediated by the activation of the PI3K/Akt pathway. Sci Rep. 2017;7:44785.
   PubMed Web of Science ®Google Scholar